Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Among patient advocates and the pharmaceutical industry there is a ...

Industry-sponsored patient advocacy groups say they find fault in the quality-adjusted life year (QALY) for technical reasons. But their stance also benefits pharmaceutical manufacturers that fund ...

President Trump’s work to lower prescription drug costs for patients will undoubtedly be one of his most significant legacies. From the legislation he recently signed to increase transparency among ph ...

We argue that while the QALY is not perfect, valid alternatives exist that address concerns and that will facilitate explicit consideration of both quality and length of life in comparative ...

Lost in the debate over how Medicare will negotiate drug prices, there's a concern by federal agencies about a metric used in determining a drug’s value. It's known as the Quality-Adjusted Life Year.

The quality-adjusted life-year (QALY) is a popular tool for value assessment but is flawed. This paper highlights potential solutions. Most value assessment research uses the quality-adjusted ...

In late March, the House Committee on Energy and Commerce advanced H.R. 485 - Protecting Health Care for All Patients Act - on a party line vote with Republicans favoring an amended version of the ...

Panelists at a session of the ISPOR 2019 annual meeting discussed the good and the bad about the quality-adjusted life-year (QALY) metric from their various perspectives. What is the value of the ...

Leela Barham sets out some wider context to the latest blog from NICE on the cost-effectiveness threshold used by the agency and highlights the opportunity for stakeholders to build their case for ...

In a party line vote, House Republicans voted to ban certain pricing metrics in federal health programs such as Medicaid, Medicare Advantage and VA Health Care. Under the proposal, titled the ...